| Acute lymphocytic leukemia
Asparlas vs Oncaspar
Side-by-side clinical, coverage, and cost comparison for acute lymphocytic leukemia.Deep comparison between: Asparlas vs Oncaspar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOncaspar has a higher rate of injection site reactions vs Asparlas based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Oncaspar but not Asparlas, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Asparlas
Oncaspar
At A Glance
IV infusion
Every 21 days
Pegylated L-asparaginase
IM injection or IV infusion
Every 14 days
PEGylated L-asparaginase
Indications
- Acute lymphocytic leukemia
- Acute lymphocytic leukemia
Dosing
Acute lymphocytic leukemia 2,500 units/m2 intravenously no more frequently than every 21 days.
Acute lymphocytic leukemia 2,500 IU/m2 (age <=21 years) or 2,000 IU/m2 (age >21 years) IM or IV, no more frequently than every 14 days.
Contraindications
- History of serious hypersensitivity reactions, including anaphylaxis, to pegylated L-asparaginase therapy
- History of serious pancreatitis during previous L-asparaginase therapy
- History of serious thrombosis during previous L-asparaginase therapy
- History of serious hemorrhagic events during previous L-asparaginase therapy
- Severe hepatic impairment
- History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR or any excipient
- History of serious thrombosis with prior L-asparaginase therapy
- History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy
- History of serious hemorrhagic events with prior L-asparaginase therapy
- Severe hepatic impairment
Adverse Reactions
Most common Elevated transaminase, bilirubin increased, pancreatitis, abnormal clotting studies, diarrhea, hypersensitivity, embolic and thrombotic events, sepsis, dyspnea, hemorrhages, fungal infection, pneumonia, arrhythmia, cardiac failure
Serious Hypersensitivity, pancreatitis, thrombosis, hemorrhage, hepatotoxicity including veno-occlusive disease
Postmarketing Veno-occlusive disease (hepatic)
Most common (>5%) Elevated transaminase, febrile neutropenia, hypertriglyceridemia, hypoalbuminemia, bilirubin increased, hyperglycemia, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, infections
Serious Anaphylaxis and serious hypersensitivity reactions, thrombosis, pancreatitis, glucose intolerance, hemorrhage, hepatotoxicity including veno-occlusive disease
Postmarketing Coagulopathy, hepatic impairment, pancreatic cyst, veno-occlusive disease, anaphylactic shock, blood cholesterol increased, hyperglycemia, hyperammonemia, osteonecrosis, hemorrhage including CNS hemorrhage, thrombosis including superior sagittal sinus thrombosis
Pharmacology
Pegylated L-asparaginase enzyme that depletes plasma asparagine by catalyzing its conversion to aspartic acid and ammonia; leukemic cells with low asparagine synthetase expression depend on exogenous asparagine for survival and are killed by its depletion.
ONCASPAR is a PEGylated L-asparaginase that catalyzes the conversion of L-asparagine to aspartic acid and ammonia, depleting plasma asparagine and killing leukemic cells that have low asparagine synthetase expression and depend on an exogenous asparagine source for survival.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Asparlas
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Oncaspar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Asparlas
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Oncaspar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Asparlas
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Oncaspar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Asparlas Patient Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Acute Lymphoblastic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AsparlasView full Asparlas profile
OncasparView full Oncaspar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.